Latest news with #RadNet
Yahoo
3 days ago
- Health
- Yahoo
RadNet acquires See-Mode to bolster AI ultrasound screening for thyroid cancer
RadNet, a DeepHealth company, has acquired See-Mode, an artificial intelligence (AI)-based ultrasound imaging developer. The US company's acquisition, the terms of which have not been publicly disclosed, will provide it with ultrasound provisions for the detection of thyroid cancer. See-Mode's AI software uses single or multinodular thyroid ultrasound images to detect nodules and produce standardised reports. The software automatically classifies nodules in accordance with the American College of Radiology's (ACR) Thyroid Imaging Reporting and Data System (TI-RADS). Research indicates that thyroid cancer is one of the fastest developing cancer diagnoses globally. Alongside breast cancer, women are most often affected by the disease. See-Mode's AI-powered thyroid ultrasound analysis system, which gained US Food and Drug Administration (FDA) clearance in September 2024, has demonstrated a 30% reduction in scan time as a result of increased workflow efficiency, said Dr Howard Berger, president and CEO of RadNet. 'Due to the inherent complexity of radiology and user and radiologist-dependent expertise, the opportunity to improve care through AI is significant. 'With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centres.' Various research indicates that there is a growing shortfall in radiologists that is set to worsen in the coming decades, making AI a compelling prospect in mitigating the shortfall by helping drive efficiencies through automation. A report by the Association of American Medical Colleges (AAMC) forecasts that the radiologist shortfall in the US could reach almost 42,000 by 2036. In the UK, a 2023 report by the Royal College of Radiologists (RCR) found that the country currently has a 30% shortfall in radiologists that is forecast to rise to 40% by 2028 unless meaningful action is taken. RadNet intends to expand the efficiencies the See-Mode acquisition will help drive across other imaging modalities including breast cancer screening in its more than two million annual ultrasound studies, Dr Berger added. According to GlobalData analysis, the global ultrasound market is forecast to reach a valuation of almost $12bn by 2024. To consolidate its market dominance in the space, GE HealthCare is also continuing to implement AI into its ultrasound provision in order to drive efficiencies. "RadNet acquires See-Mode to bolster AI ultrasound screening for thyroid cancer" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Techday NZ
3 days ago
- Health
- Techday NZ
DeepHealth boosts ultrasound AI by integrating See-Mode team
DeepHealth will incorporate See-Mode Technologies' expertise and AI technologies for thyroid and breast ultrasound into its population health solutions following RadNet's acquisition of See-Mode Technologies. See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports. The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women. Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant." Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings." See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings. Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound." Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth." According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations. Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers. See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
Yahoo
26-05-2025
- Business
- Yahoo
What Makes RadNet (RDNT) an Investment Bet?
Baron Funds, an investment management company, released its 'Baron Small Cap Fund' first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter of 2025, the fund was down 9.07% (Institutional Shares) compared to the Russell 2000 Growth Index's (the Index) -11.12% return. Small-cap stocks continued to underperform larger market caps meaningfully, so the Fund lagged the Russell 3000 Index, which fell 4.72% in the quarter. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Small Cap Fund highlighted stocks such as RadNet, Inc. (NASDAQ:RDNT). Headquartered in Los Angeles, California, RadNet, Inc. (NASDAQ:RDNT) provides outpatient diagnostic imaging services. The one-month return of RadNet, Inc. (NASDAQ:RDNT) was 12.63%, and its shares lost 3.30% of their value over the last 52 weeks. On May 23, 2025, RadNet, Inc. (NASDAQ:RDNT) stock closed at $56.61 per share with a market capitalization of $4.247 billion. Baron Small Cap Fund stated the following regarding RadNet, Inc. (NASDAQ:RDNT) in its Q1 2025 investor letter: "During the quarter, we bought shares of RadNet, Inc. (NASDAQ:RDNT), the largest owner and operator of fixed-site, freestanding diagnostic imaging centers in the U.S, with 399 locations. The company's imaging centers offer multi-modality imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and other related procedures. The company develops leading positions in regional markets to leverage operational efficiencies and contracting benefits with health plans. Currently, the company has a strong regional presence in California, Maryland, New York, and New Jersey. A radiologist studying a monitor with a detailed image of a lung cancer tumor. RadNet, Inc. (NASDAQ:RDNT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 26 hedge fund portfolios held RadNet, Inc. (NASDAQ:RDNT) at the end of the fourth quarter which was 29 in the previous quarter. RadNet, Inc. (NASDAQ:RDNT) reported revenue of $471.4 million, an increase of 9.2% year-over-year. While we acknowledge the potential of RadNet, Inc. (NASDAQ:RDNT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered RadNet, Inc. (NASDAQ:RDNT) and shared Baron Health Care Fund's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
1 Safe-and-Steady Stock Worth Investigating and 2 to Ignore
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. That said, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need. Rolling One-Year Beta: 0.94 With over 350 imaging facilities across seven states and a growing artificial intelligence division, RadNet (NASDAQ:RDNT) operates a network of outpatient diagnostic imaging centers across the United States, offering services like MRI, CT scans, PET scans, mammography, and X-rays. Why Does RDNT Fall Short? Subscale operations are evident in its revenue base of $1.87 billion, meaning it has fewer distribution channels than its larger rivals Day-to-day expenses have swelled relative to revenue over the last two years as its adjusted operating margin fell by 1.3 percentage points Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 3.9 percentage points At $58 per share, RadNet trades at 109.8x forward P/E. Check out our free in-depth research report to learn more about why RDNT doesn't pass our bar. Rolling One-Year Beta: 0.88 Founded during the post-World War II economic boom when businesses needed temporary workers, ManpowerGroup (NYSE:MAN) connects millions of people to employment opportunities through its global network of staffing, recruitment, and workforce management services. Why Do We Avoid MAN? Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Sales are expected to decline once again over the next 12 months as it continues working through a challenging demand environment Sales were less profitable over the last five years as its earnings per share fell by 19.7% annually, worse than its revenue declines ManpowerGroup's stock price of $42.72 implies a valuation ratio of 10.2x forward P/E. Read our free research report to see why you should think twice about including MAN in your portfolio, it's free. Rolling One-Year Beta: 0.34 Spun off as an independent company from PepsiCo, Yum! Brands (NYSE:YUM) is a multinational corporation that owns KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill. Why Could YUM Be a Winner? Fast expansion of new restaurants indicates an aggressive approach to attacking untapped market opportunities Highly efficient business model is illustrated by its impressive 32.1% operating margin Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends Yum! Brands is trading at $148.02 per share, or 23.8x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
SHINE Announces Two Strategic Appointments to Advance Fusion Technology and Market Expansion
Healthcare technology leader Dr. Gregory Sorensen joins Board of Directors; Defense expert Col. (Ret.) Gregory Van Dyk joins as Strategic Advisor JANESVILLE, Wis., May 21, 2025 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company with commercialized platforms in industrial testing and medical isotopes, today announced the appointments of Dr. Gregory Sorensen, co-founder of DeepHealth and Chief Science Officer of RadNet, and Col. (Ret.) Gregory K. Van Dyk, U.S. Air Force, as strategic advisor to its Board of Directors. These appointments bring deep expertise in healthcare technology and national security to SHINE as the company expands the reach of its fusion applications across commercial and defense markets. "Fusion technology provides real-world solutions to big infrastructure problems in highly specialized markets," said Greg Piefer, founder and CEO of SHINE. "These appointments expand our ability to understand and access these markets quickly. Dr. Sorensen is a strong addition to our already distinguished board, having rare depth in the healthcare space that spans founding, growing, and selling startups through executive operations at multinational conglomerates. Col. Van Dyk brings a career of leadership and widespread connectivity in the radiation effects testing arena, with a specific focus on the effects of DT fusion neutrons." Dr. Sorensen: Guiding Commercial Strategy and Innovation Dr. Sorensen brings decades of experience at the intersection of healthcare, imaging, and technology. As co-founder of DeepHealth (now RadNet's AI division) and former President and CEO of Siemens Healthcare North America, he has led the development and commercialization of transformative medical technologies. He will advise SHINE on strategic growth initiatives, partnerships, and the expansion of its fusion-enabled medical isotope business. "SHINE represents the promise of fusion – not as a science experiment, but as a real-world solution," said Dr. Sorensen. "I'm excited and honored to help guide the company's growth into new healthcare and commercial markets." Col. (Ret.) Van Dyk: Advancing National Security through Fusion Col. (Ret.) Van Dyk, Ph.D. joins SHINE following a distinguished 22-year career in the U.S. Air Force, where he specialized in nuclear engineering, fusion technology, and strategic deterrence. He previously led the Department of Defense's Fusion for National Security initiative and managed a $207 million annual R&D portfolio at the National Nuclear Security Administration along with leading two multi-billion-dollar programs in the Department of Defense. His appointment comes at a critical time as SHINE expands FLARE (Fusion Linear Accelerator for Radiation Effects), a high-energy neutron testing service that enables defense contractors to evaluate the resilience of microelectronics and mission-critical systems in extreme radiation environments. "SHINE's fusion platform is practical, innovative, and timely," said Van Dyk. "FLARE offers a new capability for understanding how our most important defense technologies perform under the toughest conditions." About SHINE Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production, processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy. Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors. View original content to download multimedia: SOURCE SHINE Technologies, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
